The Interplay Between Genetic Risk Factors and Proteolytic Dysregulation in the Pathophysiology of Inflammatory Bowel Disease

J Crohns Colitis. 2020 Sep 7;14(8):1149-1161. doi: 10.1093/ecco-jcc/jjaa033.

Abstract

Crohn's disease [CD] and ulcerative colitis [UC] are the two main forms of inflammatory bowel disease [IBD]. Previous studies reported increased levels of proteolytic activity in stool and tissue samples from IBD patients, whereas the re-establishment of the proteolytic balance abrogates the development of experimental colitis. Furthermore, recent data suggest that IBD occurs in genetically predisposed individuals who develop an abnormal immune response to intestinal microbes once exposed to environmental triggers. In this review, we highlight the role of proteases in IBD pathophysiology, and we showcase how the main cellular pathways associated with IBD influence proteolytic unbalance and how functional proteomics are allowing the unambiguous identification of dysregulated proteases in IBD, paving the way to the development of new protease inhibitors as a new potential treatment.

Keywords: Crohn’s disease; NOD2; Proteases; autophagy; endoplasmic reticulum stress; inflammatory bowel disease; ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / enzymology
  • Colitis, Ulcerative* / genetics
  • Colitis, Ulcerative* / immunology
  • Crohn Disease* / drug therapy
  • Crohn Disease* / enzymology
  • Crohn Disease* / genetics
  • Gene-Environment Interaction
  • Genetic Predisposition to Disease
  • Humans
  • Immunity, Mucosal / genetics*
  • Peptide Hydrolases / metabolism*
  • Pharmacogenetics
  • Protease Inhibitors / pharmacology
  • Risk Factors

Substances

  • Protease Inhibitors
  • Peptide Hydrolases